Miriplatin,a novel lipophilic platinum complex has been developed to treat hepatocellular carcinoma.An improvd synthetic route was designed and used to prepare the target compound.The intermediate Pt(C6H14N2)(Ⅰ)2 was synthesized from K2PtC14,KI and (1R,2R)-1,2-cyclohexanediamine,Pt(C6H14N2)(Ⅰ)2 was reacted with AgNO3 to prepare Pt(C6H14N2)(H2O)2(NO3)2 solution then was subsequently reacted with CH3(CH2)12COONa in n-butanol to give target compound with satisfied yield 8l％(based on Pt(C6H14N2)I2).The structure of the target compound was identified by elemental analysis,ESI-MS,FT-IR,1H-NMR,thermal analysis,the structure was consistent with the target compound.
参考文献
| [1] | Fujiyama S;Shibata J;Maeda S;Tanaka M;Noumaru S;Sato K;Tomita K .Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol.[J].The British journal of cancer,2003(9):1614-1619. |
| [2] | Kishimoto S;Noguchi T;Yamaoka T;Fukushima S;Takeuchi Y .In vitro release of SM-11355, cis(((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)) platinum(II) suspended in lipiodol.[J].Biological & pharmaceutical bulletin,2000(5):637-640. |
| [3] | Okusaka T;Okada S;Nakanishi T;Fujiyama S;Kubo Y .Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma.[J].Investigational New Drugs: The Journal of New Anticancer Agents,2004(2):169-176. |
| [4] | Maeda M;Sasaki T .Liposoluble platinum (Ⅱ) complex and preparation thereof[P].EUR,0193936(B1),1986-03-05. |
| [5] | Tanno N;Kishimoto H;Nakatsu M .Fat soluble platinum (Ⅱ) complex hydrate[P].JPN,11315088(A),1999-11-16. |
| [6] | Yokoyama T;Kishimoto H .Method for preparing platinum complex[P].JPN,2004083508 (A),2004-03-18. |
| [7] | 王庆琨,普绍平,栾春芳,丛艳伟,张琪,贝玉祥.铂类抗肿瘤药物米铂的合成及结构表征[J].中国新药杂志,2011(17):1715-1717. |
| [8] | 王庆琨,普绍平,朱泽兵,李学杰,王蒙,黄天俊.抗肿瘤药米铂的一种新合成方法及结构表征[J].中国药物化学杂志,2011(03):213-215. |
上一张
下一张
上一张
下一张
计量
- 下载量()
- 访问量()
文章评分
- 您的评分：
-
10%
-
20%
-
30%
-
40%
-
50%